Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-01-31

FDA Approved: EDURANT — Supplemental Application (Janssen Products, LP)

View source ↗

Summary

FDA approved a supplemental application for Edurant (rilpivirine hydrochloride) submitted by Janssen Products, LP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Edurant (rilpivirine)

Snippet

SUPPL AP for EDURANT (RILPIVIRINE HYDROCHLORIDE)